State by state: where psychedelic-assisted therapy rules are shifting in 2026

The regulatory landscape for psychedelic-assisted therapy remains a state-by-state patchwork. A small group of states has established licensed frameworks; others permit only research or explicitly unregulated activity; most sit somewhere in between, with ketamine clinics operating under standard medical practice rules.

For transactions, this means the state a practice operates in is not background detail — it is a core underwriting input. Buyers are asking earlier and more precisely about state licensure structures, telehealth rules that affect follow-up care, and whether any program element depends on a regulatory posture that could change.

Sellers can get ahead of these questions. A clear, written summary of how each clinical program complies with current state law — prepared with counsel — has become one of the most valuable documents in a data room.

Limneo perspective: in some states, a licensed partner must be involved in a practice transition. Limneo tracks these requirements and will suggest a licensed partner when a deal reaches the introduction stage in those states.